The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study
Open accessAbstract
Background Specific immunotherapy is the only currently available allergen‐orientated treatment able to modify the natural history of respiratory allergic diseases. Safety and clinical efficacy of this treatment are well documented, but evidence about the ability to reduce new sensitizations is still poor. Objective We report a retrospective study conducted in order to assess the prevention of new sensitizations in monosensitized subjects treated with specific immunotherapy vs. monosensitized patients treated with anti‐allergic drugs. Methods 8396 monosensitized patients with respiratory symptoms were selected according to an open, retrospective design. Group A included 7182 patients submitted to specific immunotherapy (and anti‐allergic drugs when needed) for 4 years and then treated with drugs for at least 3 years. Group B included 1214 patients treated only with drugs for at least 7 years. All patients underwent prick test with a standard panel of allergens and total and specific IgE determination before and after 4 years of treatment and again 3 years later. Results Groups were well balanced. Polysensitized subjects were 23.75% in Group A and 68.03% in Group B after 4 years (P < 0.0001) and 26.95% and 76.77%, respectively, after 7 years (P < 0.0001). Asthmatic subjects were more prone to develop polysensitization in comparison to subjects suffering only from rhinitis (32.14% instead of 27.29% after 4 years, 36.5% instead of 31.33% after 7 years; P < 0.0001). Specific IgE decreased by 24.11% in Group A and increased by 23.87% in Group B (P < 0.0001). Total IgE decreased by 17.53% in Group A and increased by 13.71% in Group B (P < 0.0001). Conclusions Specific immunotherapy was observed retrospectively to reduce new sensitizations in monosensitized subjects suffering from respiratory allergic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“AIT is also thought to help halt the progression of allergic disease, including prevention of new allergic sensitivities and the development of asthma.1624,1626,1678,1797,1798,1824-1826”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1626]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
Durham, S. R., Walker, S. M., Varga, E., Jacobson, M. R., O'Brien, F., Noble, W. J., Till, S. J., Hamid, Q. A., & Nouri‐Aria, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410702 · Cited by 1,371
PROPHYLACTIC INOCULATION AGAINST HAY FEVER
Noon, L. (1911) · The Lancet · doi:10.1016/s0140-6736(00)78276-6 · Cited by 1,343
Punnonen, J., Aversa, G., Cocks, B. G., McKenzie, A. N., Menon, S., Zurawski, G., Malefyt, R. D. W., & de Vries, J. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3730 · Cited by 1,101
Recombinant human interleukin 5 is a selective activator of human eosinophil function.
Lopez, A. F., Sanderson, C. J., Gamble, J. R., Campbell, H. D., Young, I., & Vadas, M. A. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.167.1.219 · Cited by 949
Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases
Bousquet, J., Lockey, R. F., Malling, H., Álvarez-Cuesta, E., Canonica, G. W., Chapman, M. D., Creticos, P. S., Dayer, J., Durham, S. R., Demoly, P. M., et al. (1998) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)63136-5 · Cited by 739
Prete, G. D., Maggi, E., Parronchi, P., Chrétien, I., Tiri, A., Macchia, D., Ricci, M., Banchereau, J., de Vries, J. E., & Romagnani, S. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4193 · Cited by 707
Roches, A. D., Paradis, L. P., Ménardo, J.-L., Bouges, S., Daurès, J., & Bousquet, J. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70069-1 · Cited by 572
Interleukin 4 is localized to and released by human mast cells.
Bradding, P. H., Feather, I. H., Howarth, P. H., Mueller, R., Roberts, J. A., Britten, K. M., Bews, J. P. A., Hunt, T. C., Okayama, Y., & Heusser, C. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.5.1381 · Cited by 571
Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.
Secrist, H., Chelen, C. J., Wen, Y., Marshall, J. D., & Umetsu, D. T. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.6.2123 · Cited by 539
von Mutius, E., Fritzsch, C., Weiland, S. K., Röll, G., & MAGNUSSEN, H. (1992) · BMJ · doi:10.1136/bmj.305.6866.1395 · Cited by 503
Research works printed but not linked: 4
- Jacobsen L, 1995, Proceedings of the XVI European Congress of Allergology and Clinical Immunology., 145
- D'Amato G, 1991, Variazioni antigeniche nei ceppi e nei lotti di Alternaria isolati in Ann Arbor e in Napoli, G Ital Allergol Immunol Clin, 1, 133
- Ebner C, 1997, a major grass pollen allergen, Clin Exp Allergy, 27, 1
- Des Roches A, 1995, Specific immunotherapy prevents the onset of new sensitizations in monosensitized children. [Abstract], J Allergy Clin Immunol, 95, 309
Cited by
Sorted by citations
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma
Program, P., & theDiagnosis, T. E. P. O. (1997) · Cited by 4,082
British Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,023
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
Brożek, J. L., Bousquet, J., Baena-Cagnani, C. E., Bonini, S., Canonica, G. W., Casale, T. B., van Wijk, R. G., Ohta, K., Zuberbier, T., & Schünemann, H. J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.047 · Cited by 1,813
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256
Metadata
- Authors
- Purello‐D'Ambrosio, F., Gangemi, S., Merendino, R. A., Isola, S., Puccinelli, P., Parmiani, S., & Ricciardi, L.
- Affiliations
- University of Messina (IT)
- ALK-Abelló (Italy) (IT)
- Corresponding author
- Gangemi, S.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2001-08
- Volume
- 31
- Issue
- 8
- Pages
- 1295-1302
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2085196853
- Cited by
- 281
- References
- 76
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 6 · 2018: 12 · 2017: 13 · 2016: 16 · 2015: 14 · 2014: 17 · 2013: 9 · 2012: 14
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical & Experimental Allergy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- allergen immunotherapy, polysensitization, allergic respiratory diseases, asthma, allergic rhinitis, antiallergic drugs, specific IgE, total IgE, allergen sensitization
- MeSH terms
- Contraindications, Administration, Inhalation, Administration, Oral, Adult, Allergens, Epitopes, Asthma, Desensitization, Immunologic, Drug Administration Schedule, Female, Follow-Up Studies, Histamine H1 Antagonists, Humans, Hypersensitivity, Delayed, Immunoglobulin E, Italy, Male, Retrospective Studies, Rhinitis, Receptors, Adrenergic, beta-2, Anti-Allergic Agents, Adrenergic beta-2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
